{
    "pmid": "41466578",
    "title": "Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases.",
    "abstract": "GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP-1RAs, or SGLT2is, vs. a weight-neutral comparator (DPP4 inhibitors, DPP4is). We performed a population-based cohort study using administrative health data from a Canadian province with universal healthcare. We included adults with type 2 diabetes (T2D) and no prior ARD initiating a GLP-1RA, SGLT2i, or DPP4i between 2014/01/01 and 2022/12/31. Incident ARD cases, including rheumatoid arthritis, psoriatic disease, axial spondyloarthritis, and systemic ARDs (SARDs; systemic lupus erythematosus, systemic sclerosis, Sj√∂gren's disease, idiopathic inflammatory myopathies, and systemic vasculitides), were identified using validated algorithms. Propensity score (PS) weighting was used to balance cohorts at treatment initiation, then hazard ratios (HRs) were estimated using Cox regression. Among 229,300 adults, 49,514 initiated GLP-1RAs, 101,925 initiated SGLT2is, and 77,861 initiated DPP4is. After PS weighting, ARD incidence per 10,000 person-years was 29.1 (95% CI, 23.5-35.5) with GLP-1RAs, 24.4 (19.8-29.7) with SGLT2is, and 27.3 (22.1-33.4) with DPP4is. Mean follow-up was 1.3-1.6 years. Relative to DPP4is, adjusted HRs of ARD were 1.04 (0.81-1.33) with GLP-1RAs and 0.93 (0.75-1.16) with SGLT2is. Risk of SARDs, but not other diseases, was lower with SGLT2is vs. DPP4is (aHR, 0.51 [0.31-0.84]). Neither GLP-1RA nor SGLT2i treatment was associated with lower ARD risk vs. DPP4is in adults with T2D; however, SGLT2i use was associated with significantly lower risk of SARDs, warranting further study.",
    "disease": "rheumatoid arthritis",
    "clean_text": "glucagon like peptide receptor agonists sodium glucose cotransporter inhibitors and risk of autoimmune rheumatic diseases glp receptor agonists glp ras and sglt inhibitors sglt is facilitate weight loss and exhibit immunomodulatory effects but their impact on the risk of developing autoimmune rheumatic diseases ards is unclear we compared ard incidence following initiation of glp ras or sglt is vs a weight neutral comparator dpp inhibitors dpp is we performed a population based cohort study using administrative health data from a canadian province with universal healthcare we included adults with type diabetes t d and no prior ard initiating a glp ra sglt i or dpp i between and incident ard cases including rheumatoid arthritis psoriatic disease axial spondyloarthritis and systemic ards sards systemic lupus erythematosus systemic sclerosis sj gren s disease idiopathic inflammatory myopathies and systemic vasculitides were identified using validated algorithms propensity score ps weighting was used to balance cohorts at treatment initiation then hazard ratios hrs were estimated using cox regression among adults initiated glp ras initiated sglt is and initiated dpp is after ps weighting ard incidence per person years was ci with glp ras with sglt is and with dpp is mean follow up was years relative to dpp is adjusted hrs of ard were with glp ras and with sglt is risk of sards but not other diseases was lower with sglt is vs dpp is ahr neither glp ra nor sglt i treatment was associated with lower ard risk vs dpp is in adults with t d however sglt i use was associated with significantly lower risk of sards warranting further study"
}